Alexion’s Costly Soliris For AHUS Raises “Cost Of Life” Issues At NICE
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE is undeniably impressed with Alexion’s Soliris for treating aHUS but wants more data to justify its eye-watering price tag.